{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 30 of 92', 'CR845-CLIN3102', '6.1.2', 'Open-label Extension Phase', 'Patients who received at least 30 doses of study drug (either placebo or active) during the', '12-week Double-blind Treatment Period and continue to meet other eligibility criteria', 'will have the option to receive open-label CR845 for an additional 52 weeks. The Open-', 'label Extension Phase will be comprised of the Open-label Treatment Period and the Follow-up', 'Period. The first visit and first dosing for the Open-label Extension Phase of the study', 'will occur during the week (+1-week window) following the Discontinuation Period.', 'Each patient will receive CR845 at a dose of 0.5 mcg/kg after each dialysis session,', '3 times per week for up to 52 weeks, whether they had been previously administered', 'placebo or CR845. Prescription dry weight will be recorded every 12 weeks; if there is a', '>10% change from the previous recorded dry weight, then the CR845 dose will be', 'adjusted.', 'During selected study weeks, patients will complete the 5-D Itch Scale.', 'Clinical laboratory tests, vital signs, adverse events, and concomitant medications will be', 'monitored throughout the Open-label Treatment Period. Blood samples for inflammatory', 'biomarkers will be collected periodically until the End-of-Treatment or Early', 'Termination Visit. An electrocardiogram will be monitored at the End-of-Treatment or', 'Early Termination Visit.', 'The number and reason(s) for missed dialysis will be recorded throughout the study. Use', 'of antipruritic medications, iron, and ESAs will be recorded throughout the Open-label', 'Treatment Period.', 'The last dose of open-label study drug will be administered at the last dialysis visit in', 'Week 52. A final safety Follow-up Visit will be conducted 7-10 days after the', 'End-of-Treatment/Early Termination Visit.', 'The study schematic is shown in Figure 1.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 32 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 31 of 92', 'CR845-CLIN3102', 'Figure 1.', 'CR845-CLIN3102 Study Schematic', 'Double-blind Phase', 'Informed', 'Screening Visit', 'Run-in Period', 'consent', 'Days -28 to -7', 'Days -7 to 1', 'Day 1 of', 'Double-blind', 'End of Double-', 'Discontinuation', 'Double-blind', 'Treatment', 'blind Treatment/', 'Period', 'Treatment', 'Period Dosing', 'Early', 'Period', 'with study drug', 'Termination', 'Day 85 to', 'Randomization', 'for 12 weeks', 'Day 85', 'Day 98', 'First dose of', 'First dialysis after', 'up to 14 days', 'double-blind', 'last dose of study', 'from End of', 'study drug', 'drug', 'Treatment/', 'Early', 'Termination', 'Open-label Extension Phase', 'Day 1 up to 1', 'Open-label', 'End of Open-label', 'Open-label', 'week following', 'Treatment Period', 'Treatment/Early', 'Follow-up/Early', 'Discontinuation', 'Dosing of', 'Termination', 'Termination', 'Period', 'open-label CR845', 'First dialysis after last', '7 to 10 days from', 'First dose of', 'for up to 52 weeks', 'dose of open-label', 'End of Treatment/', 'open-label CR845', 'CR845', 'Early Termination', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 33 of 95']\n\n###\n\n", "completion": "END"}